KQTD-126
/ XtalPi
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 25, 2026
XtalPi a Boston- and Shenzhen-based AI and robotics-driven drug discovery company, submitted an Investigational New Drug application to the US FDA for KQTD-126, a gut-restricted pan-TRK inhibitor being developed for chronic intestinal pain associated with irritable bowel syndrome and inflammatory bowel disease.
(AllSci Corp)
IND • Inflammatory Bowel Disease
1 to 1
Of
1
Go to page
1